Synonyms: Phenylbenzothiazole-PEG4-OH | SPG-302
Compound class:
Synthetic organic
Comment: SPG302 induces synaptogenic regenerative actions in neural tissues [1-2]. Mechanistically SPG302 targets a regulator of the F-actin-based cytoskeleton to increase dendritic spine density and promote the formation of new synapses. It increases the density of axospinous glutamatergic synapses in Alzheimer's disease model mice.
|
|
No information available. |
Summary of Clinical Use |
Spinogenix are developing SPG302 as a treatment for amyotrophic lateral sclerosis (ALS). The FDA designated SPG302 as an orphan drug for ALS in April 2021. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT05882695 | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants | Phase 1 Interventional | Spinogenix |